Should standard chemotherapy regimens be altered in favor of small molecules? iFCG for frontline CLL
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Results of Phase Ib/II study of ricolinostat in multiple myeloma
Azacitidine/HDAC inhibitor combination for high risk AML: a promising pilot study